Cloud PR Wire

Author: Chain Wire

  • Data Accounting Selected in 2026 to Conduct Financial Audits in EU

    Warnickshire, UK, October 21st, 2026, FinanceWire

    Data Accounting Highlights Its Approach to Financial Investigations and Announces International Expansion and AI Assistant Launch

    Supporting financial transparency through forensic accounting, cross-border financial analysis, and assistance for individuals affected by financial losses.

    Data Accounting continues to develop its capabilities in financial analysis, forensic accounting, and international compliance, helping businesses and individuals navigate complex financial situations.

    As part of its international development strategy, Data Accounting is preparing to expand its presence across the United Arab Emirates, Australia and Singapore in late 2026 and early 2027. The planned expansion reflects the firm’s intention to broaden its international reach and support individuals and businesses dealing with complex financial matters across different jurisdictions.

    Alongside this expansion, Data Accounting is developing a new AI-powered assistant, scheduled for launch in the first quarter of 2027. The assistant is intended to help individuals who have suffered financial losses, including those arising from potentially unsuitable financial advice or unclear regulatory processes, identify the nature of their concerns, organize relevant information and prepare their cases for review by Data Accounting’s team. The initiative aims to make the initial assessment process more accessible and help individuals understand what information may be relevant to their circumstances.

    As financial transactions become increasingly international, the need for accurate documentation, reliable financial records, and effective oversight continues to grow. Data Accounting focuses on examining financial information, reviewing transaction histories, and identifying inconsistencies that may require further investigation or clarification.

    Its work encompasses the analysis of financial statements, accounting documentation, tax-related records, and cross-border fund movements. Through structured review procedures and analytical techniques, the firm aims to help identify discrepancies, improve financial transparency, and support informed decision-making.

    Forensic accounting can play an important role in understanding unusual transaction patterns, assessing the completeness of financial records, and identifying potential weaknesses in accounting or compliance procedures. Where concerns arise, a systematic examination of the available evidence can help clarify the circumstances and determine whether further professional or legal review may be appropriate.

    Financial Support for Businesses and Individuals

    Financial difficulties can affect both businesses and private individuals. In particular, individuals who have suffered financial losses may face uncertainty when trying to understand what happened, establish the status of their funds, or determine what options may be available to them.

    Data Accounting aims to assist individuals affected by financial losses by helping them review relevant financial documentation, organize transaction records, and examine the circumstances surrounding their cases. This includes cases in which individuals have concerns about financial advice they received or difficulties understanding regulatory processes. Depending on the situation, this work may help identify discrepancies, clarify the movement of funds, and establish a clearer picture of the available evidence.

    The planned AI assistant will provide an additional starting point for individuals seeking to explain their circumstances and organize information for assessment by the firm’s team. Each case will require an individual review, and potential next steps will depend on the circumstances, the documentation available, and the relevant legal and regulatory framework. Where appropriate, individuals may need to seek independent legal advice or contact the relevant financial institution or competent authority.

    For businesses, sound financial oversight remains equally important. Companies operating across borders often manage international suppliers, overseas payments, multi-country payroll arrangements, and complex tax obligations. Weak documentation or inadequate internal controls can create financial uncertainty, operational difficulties, and compliance risks.

    Data Accounting supports businesses seeking assistance with international accounting, tax advisory, financial reviews, and administrative processes. Its approach emphasizes accurate record-keeping, structured analysis, and the identification of potential weaknesses that may benefit from further attention.

    Supporting Transparency Through Financial Analysis

    Financial investigations require attention to detail, a methodical approach to evidence, and a clear understanding of accounting principles and applicable compliance requirements.

    Data Accounting’s services focus on helping clients assess financial information, examine unusual transaction patterns, and obtain greater clarity regarding accounting and administrative matters. Depending on the circumstances and the scope of an engagement, this work may support internal reviews, financial assessments, or further independent professional examination.

    By helping clients organize documentation and understand complex financial information, the firm seeks to support more informed decisions and improved financial accountability.

    The planned international expansion and AI assistant launch represent further steps in Data Accounting’s development, combining its existing financial analysis capabilities with new ways for individuals and businesses to engage with the firm.

    About Data Accounting

    Data Accounting provides financial and accounting-related services for businesses and individuals seeking greater clarity and transparency in financial matters. Its areas of focus include international accounting, tax advisory, financial analysis, administrative support, and forensic accounting-related reviews.

    The firm aims to help clients understand complex financial information, improve documentation practices, examine financial discrepancies, and identify opportunities to strengthen accounting and compliance procedures.

    For more information about Data Accounting and its services, visit https://data-accounting.com/.

    Contact

    Jackie Cox
    Data Accounting
    reception@mail-data-accounting.com

  • INmune Bio Establishes Global Commercialization Framework for Ebstrocel™ Through Strategic Agreement with Uniphar

    Boca Raton, Florida, October 21st, 2026, FinanceWire

    INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a late-stage biotechnology company focused on inflammation and immunology, today announced that it has entered into a Master Services Agreement with Uniphar Durbin Ireland Limited (“Uniphar”) establishing a scalable framework to support international access, distribution and commercialization of Ebstrocel™, the Company’s allogeneic stromal cell therapy for Recessive Dystrophic Epidermolysis Bullosa (RDEB). INmune Bio initially intends to use the framework to pursue named-patient access in selected European countries and in the Middle East and North Africa (MENA), subject to applicable law and country-specific statements of work. The relationship may subsequently expand across Europe and other territories by mutual agreement.

    The Company expects named-patient access to be an important component of its international commercialization strategy for Ebstrocel™. Where permitted by local law and implemented through statements of work, this pathway may allow physicians to request Ebstrocel™ for individual eligible patients before local marketing approval or broad commercial availability.

    The Uniphar framework is designed to provide the Company with scalable international commercial infrastructure, beginning with named-patient supply, and potentially expanding to broader commercial distribution as regulatory approvals, pricing and reimbursement are secured in individual countries. Depending on the services agreed in individual statements of work, Uniphar may support regulatory feasibility assessments, market access, product storage and distribution, healthcare-provider and treatment-site onboarding, order-to-cash services, medical information, pharmacovigilance support and end-to-end shipment tracking. By leveraging Uniphar’s established infrastructure rather than building country-by-country capabilities internally, the Company believes this model provides a capital-efficient path to establish Ebstrocel™’s international commercial footprint and scale as additional markets become available.

    “This agreement marks an important step in moving Ebstrocel™ from clinical development toward commercialization and bringing Ebstrocel to patients internationally,” said David Moss, Chief Executive Officer of INmune Bio. “Uniphar provides access to established market-access, distribution and order-to-cash capabilities across multiple international markets without requiring INmune Bio to build those capabilities country by country. We believe this provides a capital-efficient way to pursue named-patient opportunities in appropriate markets while building the physician relationships, treatment-center experience and commercial infrastructure needed to support broader international commercialization.”

     “We are pleased to partner with INmune Bio as it prepares Ebstrocel for international commercialization,” said Ruth Rostron, Head of Expanded Access at Uniphar. “Uniphar has built an integrated global platform to help innovative medicines navigate the complexities of international access, distribution and commercialization. We believe our infrastructure and experience are well suited to support INmune Bio’s strategy for Ebstrocel, beginning with named-patient access opportunities and expanding as the product progresses through its regulatory and commercial journey.”

    About Ebstrocel™

    Ebstrocel™ (pobistrocel) is INmune Bio’s investigational, pooled, allogeneic, human umbilical cord-derived mesenchymal stromal cell therapy being developed through the Company’s CORDStrom™ platform for the treatment of RDEB. The platform is designed to address donor variability and manufacturing inconsistency. Ebstrocel™ is investigational and has not been approved by the FDA, MHRA, EMA or any other regulatory authority.

    About Uniphar Plc.

    Uniphar is a trusted global partner to pharma, medtech and biotech, delivering solutions that connect medicines and technologies with patients worldwide. With over 57 years of experience and partnerships with 200+ multinational clients, Uniphar combines deep expertise, global infrastructure and market insight to meet the evolving needs of the life sciences sector.

    Uniphar Pharma integrates Development, Clinical, Access, Medical, Commercial, Distribution and Global Sourcing to support the full product lifecycle – from early-stage research through to commercialization and beyond. Uniphar’s unified platform spans regulatory strategy, clinical trial support, medical affairs, market access, patient engagement, commercial services, distribution and supply chain.

    Operating across 160 countries with a global team of 3,600+, Uniphar bridges manufacturers, healthcare providers, and patients — accelerating access to innovative therapies, improving patient outcomes, and delivering value across the healthcare ecosystem.

    From molecule to market and beyond.

    For more information, please visit www.uniphar.com 

    About INmune Bio Inc.

    INmune Bio Inc. is a publicly traded (NASDAQ: INMB), late-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. Moving beyond early-stage exploration, the Company’s clinical-development strategy centers on advanced precision medicine, matching drug mechanisms directly to patient biology to optimize clinical outcomes.

    INmune Bio is actively advancing two late-stage product platforms toward registrational milestones:

    • CORDStrom™: A proprietary, pooled, allogeneic, human umbilical cord-derived mesenchymal stromal cell platform engineered to address the historical clinical challenges of donor variability and manufacturing inconsistency. Following successful clinical readouts in RDEB, the platform is transitioning toward regulatory and commercial readiness, with an MAA planned for the UK MHRA in 2026 and EU EMA in 2027, alongside a planned U.S. regulatory pathway and development of international access and distribution infrastructure.
    • XPro1595™: A Dominant-Negative Tumor Necrosis Factor (DN-TNF) platform that selectively neutralizes soluble TNF (sTNF) to reduce pathological neuroinflammation without compromising protective immune function. Backed by recently granted FDA Fast Track designation and successful regulatory alignment from an End-of-Phase 2 meeting, XPro1595™ is positioned for an integrated Phase 2b/3 seamless adaptive registrational program in neuroinflammation-enriched early Alzheimer’s disease.

    To learn more about INmune Bio’s pipeline and its approach to harnessing the innate immune system, please visit www.inmunebio.com.

    Forward Looking Statements

    The Company’s product candidates are investigational, and there can be no assurance that any clinical, regulatory or commercial objective will be achieved. Any statements contained in this press release related to the development or commercialization of product candidates and other business and financial matters, including without limitation, trial results and data, timing of key milestones, future plans or expectations, the scope and implementation of the Uniphar relationship, the execution of statements of work, the availability and timing of named-patient or expanded-access sales, potential revenue, potential expansion across Europe or into Latin America, the anticipated capital efficiency of the distribution model, and the prospects for receiving regulatory approval or commercializing or selling any product or drug candidates, may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to several risks and uncertainties. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements because of these risks and uncertainties. CORDStrom™ (EbstrocelTM, pobistrocel), XPro1595™ (XPro™, pegipanermin), and INKmune™ have either finished clinical trials, are still in clinical trials or are preparing to start clinical trials and have not been approved by the US Food and Drug Administration (FDA), the UK MHRA or any regulatory body and there cannot be any assurance that they will be approved by the FDA, the UK MHRA or any regulatory body or that any specific results will be achieved. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to produce more drug for clinical trials; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Company’s filings with the Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K, the Company’s Quarterly Reports on Form 10-Q and the Company’s Current Reports on Form 8-K. The Company assumes no obligation to update any forward-looking statements to reflect any event or circumstance that may arise after the date of this release.

    INmune Bio Contacts: 

    David Moss 

    Chief Executive Officer 

    (561) 710-0512 

    info@inmunebio.com

    Daniel Carlson 

    Head of Investor Relations 

    (415) 509-4590 

    dcarlson@inmunebio.com

    Uniphar Contacts:

    Media Contacts:

    Uniphar: Heather.Hopkin@teamtala.com and Beth.Oshea@teamtala.com

    Contact

    Uniphar
    NPS_Ebstrocel@uniphar.com

  • Data Accounting Selected in 2026 to Conduct Financial Audits in EU

    Warnickshire, UK, October 21st, 2026, FinanceWire

    Data Accounting Highlights Its Approach to Financial Investigations and Announces International Expansion and AI Assistant Launch

    Supporting financial transparency through forensic accounting, cross-border financial analysis, and assistance for individuals affected by financial losses.

    Data Accounting continues to develop its capabilities in financial analysis, forensic accounting, and international compliance, helping businesses and individuals navigate complex financial situations.

    As part of its international development strategy, Data Accounting is preparing to expand its presence across the United Arab Emirates, Australia and Singapore in late 2026 and early 2027. The planned expansion reflects the firm’s intention to broaden its international reach and support individuals and businesses dealing with complex financial matters across different jurisdictions.

    Alongside this expansion, Data Accounting is developing a new AI-powered assistant, scheduled for launch in the first quarter of 2027. The assistant is intended to help individuals who have suffered financial losses, including those arising from potentially unsuitable financial advice or unclear regulatory processes, identify the nature of their concerns, organize relevant information and prepare their cases for review by Data Accounting’s team. The initiative aims to make the initial assessment process more accessible and help individuals understand what information may be relevant to their circumstances.

    As financial transactions become increasingly international, the need for accurate documentation, reliable financial records, and effective oversight continues to grow. Data Accounting focuses on examining financial information, reviewing transaction histories, and identifying inconsistencies that may require further investigation or clarification.

    Its work encompasses the analysis of financial statements, accounting documentation, tax-related records, and cross-border fund movements. Through structured review procedures and analytical techniques, the firm aims to help identify discrepancies, improve financial transparency, and support informed decision-making.

    Forensic accounting can play an important role in understanding unusual transaction patterns, assessing the completeness of financial records, and identifying potential weaknesses in accounting or compliance procedures. Where concerns arise, a systematic examination of the available evidence can help clarify the circumstances and determine whether further professional or legal review may be appropriate.

    Financial Support for Businesses and Individuals

    Financial difficulties can affect both businesses and private individuals. In particular, individuals who have suffered financial losses may face uncertainty when trying to understand what happened, establish the status of their funds, or determine what options may be available to them.

    Data Accounting aims to assist individuals affected by financial losses by helping them review relevant financial documentation, organize transaction records, and examine the circumstances surrounding their cases. This includes cases in which individuals have concerns about financial advice they received or difficulties understanding regulatory processes. Depending on the situation, this work may help identify discrepancies, clarify the movement of funds, and establish a clearer picture of the available evidence.

    The planned AI assistant will provide an additional starting point for individuals seeking to explain their circumstances and organize information for assessment by the firm’s team. Each case will require an individual review, and potential next steps will depend on the circumstances, the documentation available, and the relevant legal and regulatory framework. Where appropriate, individuals may need to seek independent legal advice or contact the relevant financial institution or competent authority.

    For businesses, sound financial oversight remains equally important. Companies operating across borders often manage international suppliers, overseas payments, multi-country payroll arrangements, and complex tax obligations. Weak documentation or inadequate internal controls can create financial uncertainty, operational difficulties, and compliance risks.

    Data Accounting supports businesses seeking assistance with international accounting, tax advisory, financial reviews, and administrative processes. Its approach emphasizes accurate record-keeping, structured analysis, and the identification of potential weaknesses that may benefit from further attention.

    Supporting Transparency Through Financial Analysis

    Financial investigations require attention to detail, a methodical approach to evidence, and a clear understanding of accounting principles and applicable compliance requirements.

    Data Accounting’s services focus on helping clients assess financial information, examine unusual transaction patterns, and obtain greater clarity regarding accounting and administrative matters. Depending on the circumstances and the scope of an engagement, this work may support internal reviews, financial assessments, or further independent professional examination.

    By helping clients organize documentation and understand complex financial information, the firm seeks to support more informed decisions and improved financial accountability.

    The planned international expansion and AI assistant launch represent further steps in Data Accounting’s development, combining its existing financial analysis capabilities with new ways for individuals and businesses to engage with the firm.

    About Data Accounting

    Data Accounting provides financial and accounting-related services for businesses and individuals seeking greater clarity and transparency in financial matters. Its areas of focus include international accounting, tax advisory, financial analysis, administrative support, and forensic accounting-related reviews.

    The firm aims to help clients understand complex financial information, improve documentation practices, examine financial discrepancies, and identify opportunities to strengthen accounting and compliance procedures.

    For more information about Data Accounting and its services, visit https://data-accounting.com/.

    Contact

    Jackie Cox
    Data Accounting
    reception@mail-data-accounting.com

  • INmune Bio Establishes Global Commercialization Framework for Ebstrocel™ Through Strategic Agreement with Uniphar

    Boca Raton, Florida, October 21st, 2026, FinanceWire

    INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a late-stage biotechnology company focused on inflammation and immunology, today announced that it has entered into a Master Services Agreement with Uniphar Durbin Ireland Limited (“Uniphar”) establishing a scalable framework to support international access, distribution and commercialization of Ebstrocel™, the Company’s allogeneic stromal cell therapy for Recessive Dystrophic Epidermolysis Bullosa (RDEB). INmune Bio initially intends to use the framework to pursue named-patient access in selected European countries and in the Middle East and North Africa (MENA), subject to applicable law and country-specific statements of work. The relationship may subsequently expand across Europe and other territories by mutual agreement.

    The Company expects named-patient access to be an important component of its international commercialization strategy for Ebstrocel™. Where permitted by local law and implemented through statements of work, this pathway may allow physicians to request Ebstrocel™ for individual eligible patients before local marketing approval or broad commercial availability.

    The Uniphar framework is designed to provide the Company with scalable international commercial infrastructure, beginning with named-patient supply, and potentially expanding to broader commercial distribution as regulatory approvals, pricing and reimbursement are secured in individual countries. Depending on the services agreed in individual statements of work, Uniphar may support regulatory feasibility assessments, market access, product storage and distribution, healthcare-provider and treatment-site onboarding, order-to-cash services, medical information, pharmacovigilance support and end-to-end shipment tracking. By leveraging Uniphar’s established infrastructure rather than building country-by-country capabilities internally, the Company believes this model provides a capital-efficient path to establish Ebstrocel™’s international commercial footprint and scale as additional markets become available.

    “This agreement marks an important step in moving Ebstrocel™ from clinical development toward commercialization and bringing Ebstrocel to patients internationally,” said David Moss, Chief Executive Officer of INmune Bio. “Uniphar provides access to established market-access, distribution and order-to-cash capabilities across multiple international markets without requiring INmune Bio to build those capabilities country by country. We believe this provides a capital-efficient way to pursue named-patient opportunities in appropriate markets while building the physician relationships, treatment-center experience and commercial infrastructure needed to support broader international commercialization.”

     “We are pleased to partner with INmune Bio as it prepares Ebstrocel for international commercialization,” said Ruth Rostron, Head of Expanded Access at Uniphar. “Uniphar has built an integrated global platform to help innovative medicines navigate the complexities of international access, distribution and commercialization. We believe our infrastructure and experience are well suited to support INmune Bio’s strategy for Ebstrocel, beginning with named-patient access opportunities and expanding as the product progresses through its regulatory and commercial journey.”

    About Ebstrocel™

    Ebstrocel™ (pobistrocel) is INmune Bio’s investigational, pooled, allogeneic, human umbilical cord-derived mesenchymal stromal cell therapy being developed through the Company’s CORDStrom™ platform for the treatment of RDEB. The platform is designed to address donor variability and manufacturing inconsistency. Ebstrocel™ is investigational and has not been approved by the FDA, MHRA, EMA or any other regulatory authority.

    About Uniphar Plc.

    Uniphar is a trusted global partner to pharma, medtech and biotech, delivering solutions that connect medicines and technologies with patients worldwide. With over 57 years of experience and partnerships with 200+ multinational clients, Uniphar combines deep expertise, global infrastructure and market insight to meet the evolving needs of the life sciences sector.

    Uniphar Pharma integrates Development, Clinical, Access, Medical, Commercial, Distribution and Global Sourcing to support the full product lifecycle – from early-stage research through to commercialization and beyond. Uniphar’s unified platform spans regulatory strategy, clinical trial support, medical affairs, market access, patient engagement, commercial services, distribution and supply chain.

    Operating across 160 countries with a global team of 3,600+, Uniphar bridges manufacturers, healthcare providers, and patients — accelerating access to innovative therapies, improving patient outcomes, and delivering value across the healthcare ecosystem.

    From molecule to market and beyond.

    For more information, please visit www.uniphar.com 

    About INmune Bio Inc.

    INmune Bio Inc. is a publicly traded (NASDAQ: INMB), late-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. Moving beyond early-stage exploration, the Company’s clinical-development strategy centers on advanced precision medicine, matching drug mechanisms directly to patient biology to optimize clinical outcomes.

    INmune Bio is actively advancing two late-stage product platforms toward registrational milestones:

    • CORDStrom™: A proprietary, pooled, allogeneic, human umbilical cord-derived mesenchymal stromal cell platform engineered to address the historical clinical challenges of donor variability and manufacturing inconsistency. Following successful clinical readouts in RDEB, the platform is transitioning toward regulatory and commercial readiness, with an MAA planned for the UK MHRA in 2026 and EU EMA in 2027, alongside a planned U.S. regulatory pathway and development of international access and distribution infrastructure.
    • XPro1595™: A Dominant-Negative Tumor Necrosis Factor (DN-TNF) platform that selectively neutralizes soluble TNF (sTNF) to reduce pathological neuroinflammation without compromising protective immune function. Backed by recently granted FDA Fast Track designation and successful regulatory alignment from an End-of-Phase 2 meeting, XPro1595™ is positioned for an integrated Phase 2b/3 seamless adaptive registrational program in neuroinflammation-enriched early Alzheimer’s disease.

    To learn more about INmune Bio’s pipeline and its approach to harnessing the innate immune system, please visit www.inmunebio.com.

    Forward Looking Statements

    The Company’s product candidates are investigational, and there can be no assurance that any clinical, regulatory or commercial objective will be achieved. Any statements contained in this press release related to the development or commercialization of product candidates and other business and financial matters, including without limitation, trial results and data, timing of key milestones, future plans or expectations, the scope and implementation of the Uniphar relationship, the execution of statements of work, the availability and timing of named-patient or expanded-access sales, potential revenue, potential expansion across Europe or into Latin America, the anticipated capital efficiency of the distribution model, and the prospects for receiving regulatory approval or commercializing or selling any product or drug candidates, may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to several risks and uncertainties. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements because of these risks and uncertainties. CORDStrom™ (EbstrocelTM, pobistrocel), XPro1595™ (XPro™, pegipanermin), and INKmune™ have either finished clinical trials, are still in clinical trials or are preparing to start clinical trials and have not been approved by the US Food and Drug Administration (FDA), the UK MHRA or any regulatory body and there cannot be any assurance that they will be approved by the FDA, the UK MHRA or any regulatory body or that any specific results will be achieved. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to produce more drug for clinical trials; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Company’s filings with the Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K, the Company’s Quarterly Reports on Form 10-Q and the Company’s Current Reports on Form 8-K. The Company assumes no obligation to update any forward-looking statements to reflect any event or circumstance that may arise after the date of this release.

    INmune Bio Contacts: 

    David Moss 

    Chief Executive Officer 

    (561) 710-0512 

    info@inmunebio.com

    Daniel Carlson 

    Head of Investor Relations 

    (415) 509-4590 

    dcarlson@inmunebio.com

    Uniphar Contacts:

    Media Contacts:

    Uniphar: Heather.Hopkin@teamtala.com and Beth.Oshea@teamtala.com

    Contact

    Uniphar
    NPS_Ebstrocel@uniphar.com

  • Injective Collaborates with BDACS to Bring Korea’s First Won-Backed Stablecoin to Onchain RWAs

    Seoul, South Korea, October 20th, 2026, FinanceWire

    Today, Injective is proud to announce that it has partnered with BDACS, the issuer of KRW1, Korea’s first stablecoin fully backed by the Korean won. Under a memorandum of understanding (MOU) signed by both companies, the two teams will work together to establish KRW1 as the first won-denominated settlement asset for real-world assets (RWAs) and tokenization use cases within the Injective ecosystem.

    The cooperation brings together a fully reserved won stablecoin and a blockchain purpose-built for finance, with a focus on institution-ready use cases for won-denominated onchain markets.

    A Won-Denominated Settlement Layer for Onchain Finance

    Stablecoins have become the settlement layer of onchain finance. Total supply across onchain markets reached a record $322 billion in May 2026, and Citi projects $1.9 trillion by 2030 in its base case.

    Nearly all of that supply is denominated in dollars. In Korea, that gap shows up as capital leaving the country. Korea’s five major exchanges have posted 18 straight months of net stablecoin outflows to offshore platforms since January 2025. The total is about 14.9 trillion won, or roughly $10.4 billion. Korean investors want onchain markets, and many would prefer to access them in won.

    Korea is one of the most active digital asset markets in the world, yet tokenized assets in Korea have largely lacked one key piece. They have had no way to settle onchain in Korean won. Without a KRW settlement asset, tokenized products are typically priced and settled in USD stablecoins, which adds FX exposure for Korean institutions and investors.

    KRW1 was designed to fill that gap. Issued by BDACS, KRW1 is fully backed 1:1 by the Korean won. Minting and redemption will be available to approved institutional partners, subject to regulatory approval.  

    The timing matches Korea’s policy direction. The government aims to finalize the Digital Asset Basic Act, the legal framework for won stablecoin issuance, by the end of 2026. The Bank of Korea has pushed for banks to anchor that market.

    Collaboration Overview

    Bringing KRW1 to Injective opens the door to won-denominated finance onchain.

    • A native Korean won onchain. KRW1 joins the Injective ecosystem, giving builders and institutions a fully reserved won stablecoin alongside Injective’s native dollar-denominated USDC stablecoin issued alongside Circle.
    • KRW markets for tokenized assets. Tokenized RWAs on Injective will be able to trade and settle directly in Korean won, without routing through USD.
    • A path onchain for Korean institutions. BDACS and Injective will work with Korean financial institutions to bring their assets onchain, settled in KRW1.
    • Compliance built into every asset. Assets issued through Injective Mint carry holder, jurisdictional, and transfer controls at the protocol level, so won-settled markets can be configured around each issuer’s requirements.
    • Growing Korea’s onchain economy. Joint initiatives will expand KRW1 adoption across the Injective ecosystem and the Korean community.

    “Bringing a Korean won settlement layer onchain is an important step for tokenized finance in Korea,” said Eric Chen, Co-founder of Injective. “Together with BDACS, we are building the foundation for Korean won markets onchain, from tokenized RWAs to institutional settlement.”

    Injective’s Infrastructure for Tokenized Finance

    Injective is purpose-built for finance, with native infrastructure for trading, tokenization, and stablecoins. More than $7.5 billion in RWA volume has been processed on Injective, and more than $1 billion in tokenized assets have been issued on the network.

    Korea’s largest companies are already building on it. In July 2026, POSCO International, South Korea’s largest trading company, and LG CNS, the technology arm of LG Group, selected Injective to issue, transfer, administer, and settle live trade receivables generated by international commerce. Four Pillars, the Korean research and infrastructure firm, operates an institutional validator on the network.

    Recent milestones include Injective Institutional Services becoming an SEC-registered transfer agent and Pineapple Financial tokenizing more than $1 billion in mortgage records onchain. Injective’s native USDC stablecoin issued by Circle is now set to be the canonical stablecoin standard for more than 20 blockchains including Cosmos and dYdX, cementing Injective’s position at the center of onchain stablecoins.

    “Without onchain won infrastructure, demand in tokenized markets will remain anchored to dollar stablecoins,” said Harry Ryoo, CEO of BDACS. “Through our partnership with Injective, we will explore how KRW1 can serve as a won settlement asset for tokenized markets, and we will expand our collaboration step by step as Korea’s regulatory framework develops.”

    This makes Injective a natural environment to test how a won stablecoin can support compliant tokenized asset markets, from issuance through secondary trading.

    Next Steps for KRW1 Integration

    This initiative marks the first step towards bringing native Korean won markets on Injective, with more to come as Korean institutions bring their assets onchain. This will directly be implemented across Injective’s wide array of onchain markets with further updates expected as specific use cases go live.

    About BDACS

    BDACS is a leading digital asset infrastructure company providing a Prime Custody Solution for corporate and institutional clients. In the first half of 2026, BDACS surpassed 80 billion KRW in assets under custody, making it Korea’s largest digital asset custodian. A registered virtual asset service provider (VASP) with the Korea Financial Intelligence Unit, BDACS holds SOC 1, ISO 27001 and ISMS certifications. BDACS issued the world’s first Korean won stablecoin, KRW1. BDACS also maintains strategic partnerships with leading financial and Web3 companies.

    About Injective

    Injective is the first blockchain purpose-built for finance, enabling users, institutions, and AI agents to trade, tokenize, and transact at scale. Proudly made in America, Injective provides foundational blockchain infrastructure for global markets, with embedded financial primitives spanning stablecoins, real-world assets, payments, and programmable perpetuals through a unified onchain engine. Injective is used by Fortune 500 companies, banks, fintechs, and governments to power an open economy where any asset can be accessed anytime, from anywhere. Builders can deploy across multiple virtual machines like WASM and EVM, connect to native financial modules, and launch markets with deep liquidity from day one. INJ is the native token powering the rapidly growing Injective ecosystem and the new internet economy.

    Website | Telegram | Discord | Blog | Twitter | Youtube | Facebook | LinkedIn | Reddit | Instagram | Orbit Newsletter

    Contact

    Sarah Cohen
    SJC PR
    sarah@sjc-pr.com

  • Injective Collaborates with BDACS to Bring Korea’s First Won-Backed Stablecoin to Onchain RWAs

    Seoul, South Korea, October 20th, 2026, FinanceWire

    Today, Injective is proud to announce that it has partnered with BDACS, the issuer of KRW1, Korea’s first stablecoin fully backed by the Korean won. Under a memorandum of understanding (MOU) signed by both companies, the two teams will work together to establish KRW1 as the first won-denominated settlement asset for real-world assets (RWAs) and tokenization use cases within the Injective ecosystem.

    The cooperation brings together a fully reserved won stablecoin and a blockchain purpose-built for finance, with a focus on institution-ready use cases for won-denominated onchain markets.

    A Won-Denominated Settlement Layer for Onchain Finance

    Stablecoins have become the settlement layer of onchain finance. Total supply across onchain markets reached a record $322 billion in May 2026, and Citi projects $1.9 trillion by 2030 in its base case.

    Nearly all of that supply is denominated in dollars. In Korea, that gap shows up as capital leaving the country. Korea’s five major exchanges have posted 18 straight months of net stablecoin outflows to offshore platforms since January 2025. The total is about 14.9 trillion won, or roughly $10.4 billion. Korean investors want onchain markets, and many would prefer to access them in won.

    Korea is one of the most active digital asset markets in the world, yet tokenized assets in Korea have largely lacked one key piece. They have had no way to settle onchain in Korean won. Without a KRW settlement asset, tokenized products are typically priced and settled in USD stablecoins, which adds FX exposure for Korean institutions and investors.

    KRW1 was designed to fill that gap. Issued by BDACS, KRW1 is fully backed 1:1 by the Korean won. Minting and redemption will be available to approved institutional partners, subject to regulatory approval.  

    The timing matches Korea’s policy direction. The government aims to finalize the Digital Asset Basic Act, the legal framework for won stablecoin issuance, by the end of 2026. The Bank of Korea has pushed for banks to anchor that market.

    Collaboration Overview

    Bringing KRW1 to Injective opens the door to won-denominated finance onchain.

    • A native Korean won onchain. KRW1 joins the Injective ecosystem, giving builders and institutions a fully reserved won stablecoin alongside Injective’s native dollar-denominated USDC stablecoin issued alongside Circle.
    • KRW markets for tokenized assets. Tokenized RWAs on Injective will be able to trade and settle directly in Korean won, without routing through USD.
    • A path onchain for Korean institutions. BDACS and Injective will work with Korean financial institutions to bring their assets onchain, settled in KRW1.
    • Compliance built into every asset. Assets issued through Injective Mint carry holder, jurisdictional, and transfer controls at the protocol level, so won-settled markets can be configured around each issuer’s requirements.
    • Growing Korea’s onchain economy. Joint initiatives will expand KRW1 adoption across the Injective ecosystem and the Korean community.

    “Bringing a Korean won settlement layer onchain is an important step for tokenized finance in Korea,” said Eric Chen, Co-founder of Injective. “Together with BDACS, we are building the foundation for Korean won markets onchain, from tokenized RWAs to institutional settlement.”

    Injective’s Infrastructure for Tokenized Finance

    Injective is purpose-built for finance, with native infrastructure for trading, tokenization, and stablecoins. More than $7.5 billion in RWA volume has been processed on Injective, and more than $1 billion in tokenized assets have been issued on the network.

    Korea’s largest companies are already building on it. In July 2026, POSCO International, South Korea’s largest trading company, and LG CNS, the technology arm of LG Group, selected Injective to issue, transfer, administer, and settle live trade receivables generated by international commerce. Four Pillars, the Korean research and infrastructure firm, operates an institutional validator on the network.

    Recent milestones include Injective Institutional Services becoming an SEC-registered transfer agent and Pineapple Financial tokenizing more than $1 billion in mortgage records onchain. Injective’s native USDC stablecoin issued by Circle is now set to be the canonical stablecoin standard for more than 20 blockchains including Cosmos and dYdX, cementing Injective’s position at the center of onchain stablecoins.

    “Without onchain won infrastructure, demand in tokenized markets will remain anchored to dollar stablecoins,” said Harry Ryoo, CEO of BDACS. “Through our partnership with Injective, we will explore how KRW1 can serve as a won settlement asset for tokenized markets, and we will expand our collaboration step by step as Korea’s regulatory framework develops.”

    This makes Injective a natural environment to test how a won stablecoin can support compliant tokenized asset markets, from issuance through secondary trading.

    Next Steps for KRW1 Integration

    This initiative marks the first step towards bringing native Korean won markets on Injective, with more to come as Korean institutions bring their assets onchain. This will directly be implemented across Injective’s wide array of onchain markets with further updates expected as specific use cases go live.

    About BDACS

    BDACS is a leading digital asset infrastructure company providing a Prime Custody Solution for corporate and institutional clients. In the first half of 2026, BDACS surpassed 80 billion KRW in assets under custody, making it Korea’s largest digital asset custodian. A registered virtual asset service provider (VASP) with the Korea Financial Intelligence Unit, BDACS holds SOC 1, ISO 27001 and ISMS certifications. BDACS issued the world’s first Korean won stablecoin, KRW1. BDACS also maintains strategic partnerships with leading financial and Web3 companies.

    About Injective

    Injective is the first blockchain purpose-built for finance, enabling users, institutions, and AI agents to trade, tokenize, and transact at scale. Proudly made in America, Injective provides foundational blockchain infrastructure for global markets, with embedded financial primitives spanning stablecoins, real-world assets, payments, and programmable perpetuals through a unified onchain engine. Injective is used by Fortune 500 companies, banks, fintechs, and governments to power an open economy where any asset can be accessed anytime, from anywhere. Builders can deploy across multiple virtual machines like WASM and EVM, connect to native financial modules, and launch markets with deep liquidity from day one. INJ is the native token powering the rapidly growing Injective ecosystem and the new internet economy.

    Website | Telegram | Discord | Blog | Twitter | Youtube | Facebook | LinkedIn | Reddit | Instagram | Orbit Newsletter

    Contact

    Sarah Cohen
    SJC PR
    sarah@sjc-pr.com

  • GRVT Burns 1.1 Million Tokens as Countdown to Grvt 2.0 Begins

    Singapore, Singapore, October 20th, 2026, Chainwire

    The discretionary buyback represents close to 1% of circulating supply and precedes four planned product milestones culminating in Grvt 2.0.

    Grvt, a self-custodial trading platform built on its own zero-knowledge (ZK) chain, announced that the Foundation’s token issuer has completed its first GRVT token buyback, purchasing and burning 1.1 million GRVT tokens on the open market.

    The transaction permanently removed close to 1% of GRVT’s circulating supply at the time of purchase. It marks the first of five milestones ahead of the planned launch of Grvt 2.0 at the end of November 2026.

    A Discretionary Buyback with On-Chain Verification

    The Foundation’s token issuer intends to conduct further buybacks on a monthly basis. Each transaction remains entirely at the issuer’s discretion, with no predetermined purchase amount or guaranteed schedule.

    Buybacks are executed through an independent execution partner, with purchased tokens transferred to a designated burn address and permanently removed from circulation.

    The transactions can be independently verified through the public buyback dashboard, which records the number of tokens purchased and burned, the percentage of circulating supply represented, cumulative burns and on-chain transaction hashes.

    “The GRVT token is an important part of the ecosystem we are building,” said Hong, co-founder and CEO of Grvt. “We welcome the issuer’s buybacks as a demonstration of its long-term commitment to the ecosystem and community. Grvt is expanding its products and markets, and the issuer’s buybacks sit alongside that as a supportive mechanism aimed at reducing circulating token supply.”

    Grvt Outlines Four Product Milestones

    The announcement follows GRVT’s token generation event in July 2026 and precedes a series of planned launches.Grvt Earn, scheduled for the End of October, will introduce yield opportunities backed by tokenized assets, with target yields of up to 11%. Potential returns are expected to derive from underlying asset cash flows, including interest, premiums and invoice-related income. Asset-supplying partners will be announced at launch. Target yields are not guaranteed.

    Stable Funding Perps, scheduled for November, will introduce perpetual futures linked to commodities, stocks, foreign exchange and indices. The contracts are planned to carry zero trading fees and use once-daily funding. Grvt aims to list more than 1,000 markets by the end of December 2026.

    Yield as Margin, also scheduled for November, will allow eligible Grvt Earn balances to support trading positions while continuing to accrue yield, subject to applicable product terms and risk parameters.

    Grvt 2.0, scheduled for the End of November, will consolidate these capabilities into a single self-custodial app, alongside a new name, visual identity, and the company’s 2027 roadmap.

    Addressing Idle Capital

    The expansion follows a survey of Grvt traders conducted earlier in 2026. Six in ten respondents reported keeping at least a quarter of their capital on the platform idle, while many reported moving funds elsewhere to pursue yields of 8% or more.

    Grvt’s upcoming products aim to reduce the separation between earning yield and deploying capital for trading.

    “Traders shouldn’t have to choose between putting their capital to work and keeping it ready to trade,” Hong said. “Grvt 2.0 is designed around a single self-custodial balance that can support both activities.”

    Founded in 2022, Grvt currently supports perpetual futures across approximately 200 cryptocurrency and real-world asset markets.

    The GRVT token launched in July 2026 and confers no ownership, profit or other economic rights.

    Further details are available in the full announcement.

    About Grvt

    Grvt is a self-custodial trading platform operating on its own zero-knowledge chain. The platform supports cryptocurrency and real-world asset perpetual futures and is developing products that allow eligible balances to earn yield while supporting trading activity.

    Learn more at grvt.io.

    Contact

    Head of Marketing
    Lesner Chua
    GRVT ASIA PTE. LTD
    lesner.chua@grvt.io

  • GRVT Burns 1.1 Million Tokens as Countdown to Grvt 2.0 Begins

    Singapore, Singapore, October 20th, 2026, Chainwire

    The discretionary buyback represents close to 1% of circulating supply and precedes four planned product milestones culminating in Grvt 2.0.

    Grvt, a self-custodial trading platform built on its own zero-knowledge (ZK) chain, announced that the Foundation’s token issuer has completed its first GRVT token buyback, purchasing and burning 1.1 million GRVT tokens on the open market.

    The transaction permanently removed close to 1% of GRVT’s circulating supply at the time of purchase. It marks the first of five milestones ahead of the planned launch of Grvt 2.0 at the end of November 2026.

    A Discretionary Buyback with On-Chain Verification

    The Foundation’s token issuer intends to conduct further buybacks on a monthly basis. Each transaction remains entirely at the issuer’s discretion, with no predetermined purchase amount or guaranteed schedule.

    Buybacks are executed through an independent execution partner, with purchased tokens transferred to a designated burn address and permanently removed from circulation.

    The transactions can be independently verified through the public buyback dashboard, which records the number of tokens purchased and burned, the percentage of circulating supply represented, cumulative burns and on-chain transaction hashes.

    “The GRVT token is an important part of the ecosystem we are building,” said Hong, co-founder and CEO of Grvt. “We welcome the issuer’s buybacks as a demonstration of its long-term commitment to the ecosystem and community. Grvt is expanding its products and markets, and the issuer’s buybacks sit alongside that as a supportive mechanism aimed at reducing circulating token supply.”

    Grvt Outlines Four Product Milestones

    The announcement follows GRVT’s token generation event in July 2026 and precedes a series of planned launches.Grvt Earn, scheduled for the End of October, will introduce yield opportunities backed by tokenized assets, with target yields of up to 11%. Potential returns are expected to derive from underlying asset cash flows, including interest, premiums and invoice-related income. Asset-supplying partners will be announced at launch. Target yields are not guaranteed.

    Stable Funding Perps, scheduled for November, will introduce perpetual futures linked to commodities, stocks, foreign exchange and indices. The contracts are planned to carry zero trading fees and use once-daily funding. Grvt aims to list more than 1,000 markets by the end of December 2026.

    Yield as Margin, also scheduled for November, will allow eligible Grvt Earn balances to support trading positions while continuing to accrue yield, subject to applicable product terms and risk parameters.

    Grvt 2.0, scheduled for the End of November, will consolidate these capabilities into a single self-custodial app, alongside a new name, visual identity, and the company’s 2027 roadmap.

    Addressing Idle Capital

    The expansion follows a survey of Grvt traders conducted earlier in 2026. Six in ten respondents reported keeping at least a quarter of their capital on the platform idle, while many reported moving funds elsewhere to pursue yields of 8% or more.

    Grvt’s upcoming products aim to reduce the separation between earning yield and deploying capital for trading.

    “Traders shouldn’t have to choose between putting their capital to work and keeping it ready to trade,” Hong said. “Grvt 2.0 is designed around a single self-custodial balance that can support both activities.”

    Founded in 2022, Grvt currently supports perpetual futures across approximately 200 cryptocurrency and real-world asset markets.

    The GRVT token launched in July 2026 and confers no ownership, profit or other economic rights.

    Further details are available in the full announcement.

    About Grvt

    Grvt is a self-custodial trading platform operating on its own zero-knowledge chain. The platform supports cryptocurrency and real-world asset perpetual futures and is developing products that allow eligible balances to earn yield while supporting trading activity.

    Learn more at grvt.io.

    Contact

    Head of Marketing
    Lesner Chua
    GRVT ASIA PTE. LTD
    lesner.chua@grvt.io

  • PrimeXBT Launches 14-Day VIP Welcome Offer, Cutting Trading Costs for All New Users

    Castries, Saint Lucia, October 19th, 2026, FinanceWire

    PrimeXBT, a global multi-asset broker and crypto asset service provider, has introduced a new VIP Welcome offer, giving all new clients automatic VIP4-tier status for their first 14 days. Activated upon registration with no additional action required, the offer provides immediate access to lower trading costs and enhanced conditions without first meeting the usual trading-volume requirements.

    During the welcome period, clients receive 15% discount on Forex and CFD spreads on broker’s PXTrader 2.0 platform, with further reductions of up to 50% on Gold and Bitcoin CFD spreads. VIP4 tier also includes 33% off Crypto Futures taker fees, 10% off Exchange spreads, 24/7 priority support and access to 10% cashback on eligible trading costs through the Rewards Center. Trading volume on MT5 counts towards VIP qualification, but VIP fee and spread discounts only apply on PXTrader 2.0.

    PrimeXBT’s VIP Tiers program offers five levels of progressively lower fees and enhanced conditions, with VIP status normally earned based on trading volume over the previous 30 days. Tier upgrades are automatic, and traders can track their progress in real time. The VIP Welcome offer gives all new clients immediate access to VIP 4 without first meeting these volume requirements. After the 14-day welcome period, clients who meet the relevant thresholds can maintain VIP 4 or progress to VIP 5.

    “Small differences in spreads and fees can be easy to overlook on a single trade, but they add up over time and can have a substantial impact on costs, particularly for high-volume traders,” said Jonatan Randin, Senior Market Analyst at PrimeXBT. “The VIP Welcome offer gives new clients the opportunity to experience our premium trading conditions from day one, alongside the charting and risk-management tools they need to plan and manage their positions.”

    The launch builds on PrimeXBT’s focus on reducing trading costs across key markets. PXTrader 2.0 offers commission-free CFD trading, with EUR/USD spreads from 0 pips. VIP conditions include spreads from $0.17 on Gold, 0.2 points on US500, 0.4 points on NASDAQ and $19 on BTC CFDs at the highest tier. Clients can also unlock VIP tiers using their Rewards Center balance, earned through tasks and trading milestones. The balance can also be used for cashback or trading bonus.

    PrimeXBT continues to strengthen its position in multi-asset trading through competitive pricing and professional tools. The VIP Welcome offer reinforces this priority, making market-leading trading conditions accessible to everyone from the very first trade.

    To learn more, users can visit PrimeXBT website.

    About PrimeXBT

    PrimeXBT is a global multi-asset broker and crypto asset service provider trusted by traders in more than 150 countries. The platform bridges traditional and digital markets within one integrated environment, redefining versatility and innovation in online trading. Clients can access Forex, CFDs on indices, commodities, shares, crypto, and Crypto Futures, as well as buy, store and exchange cryptocurrencies. This unified experience extends across both the native PXTrader 2.0 platform and MetaTrader 5, supported by advanced risk-management tools and a wide range of funding options in crypto, fiat and local payment methods. Since 2018, PrimeXBT has focused on empowering traders through broad multi-asset access, fair and transparent conditions, professional-grade technology and dedicated human support. By combining expertise, trust and a client-first approach, PrimeXBT sets a benchmark of excellence in the financial industry and provides traders with the tools they need to trade, grow and succeed with confidence.

    Disclaimer: The content provided here is for informational purposes only and is not intended as personal investment advice and does not constitute a solicitation or invitation to engage in any financial transactions, investments, or related activities. Past performance is not a reliable indicator of future results. The financial products offered by the Company are complex and come with a high risk of losing money rapidly due to leverage. These products may not be suitable for all investors. Before engaging, you should consider whether you understand how these leveraged products work and whether you can afford the high risk of losing your money. The Company does not accept clients from the Restricted Jurisdictions as indicated on its website / T&Cs. Some products and services, including MT5, may not be available in your jurisdiction. The applicable legal entity and its respective products and services depend on the client’s country of residence and the entity with which the client has established a contractual relationship during registration.

    Contact

    PrimeXBT
    pr@primexbt.com

  • PrimeXBT Launches 14-Day VIP Welcome Offer, Cutting Trading Costs for All New Users

    Castries, Saint Lucia, October 19th, 2026, FinanceWire

    PrimeXBT, a global multi-asset broker and crypto asset service provider, has introduced a new VIP Welcome offer, giving all new clients automatic VIP4-tier status for their first 14 days. Activated upon registration with no additional action required, the offer provides immediate access to lower trading costs and enhanced conditions without first meeting the usual trading-volume requirements.

    During the welcome period, clients receive 15% discount on Forex and CFD spreads on broker’s PXTrader 2.0 platform, with further reductions of up to 50% on Gold and Bitcoin CFD spreads. VIP4 tier also includes 33% off Crypto Futures taker fees, 10% off Exchange spreads, 24/7 priority support and access to 10% cashback on eligible trading costs through the Rewards Center. Trading volume on MT5 counts towards VIP qualification, but VIP fee and spread discounts only apply on PXTrader 2.0.

    PrimeXBT’s VIP Tiers program offers five levels of progressively lower fees and enhanced conditions, with VIP status normally earned based on trading volume over the previous 30 days. Tier upgrades are automatic, and traders can track their progress in real time. The VIP Welcome offer gives all new clients immediate access to VIP 4 without first meeting these volume requirements. After the 14-day welcome period, clients who meet the relevant thresholds can maintain VIP 4 or progress to VIP 5.

    “Small differences in spreads and fees can be easy to overlook on a single trade, but they add up over time and can have a substantial impact on costs, particularly for high-volume traders,” said Jonatan Randin, Senior Market Analyst at PrimeXBT. “The VIP Welcome offer gives new clients the opportunity to experience our premium trading conditions from day one, alongside the charting and risk-management tools they need to plan and manage their positions.”

    The launch builds on PrimeXBT’s focus on reducing trading costs across key markets. PXTrader 2.0 offers commission-free CFD trading, with EUR/USD spreads from 0 pips. VIP conditions include spreads from $0.17 on Gold, 0.2 points on US500, 0.4 points on NASDAQ and $19 on BTC CFDs at the highest tier. Clients can also unlock VIP tiers using their Rewards Center balance, earned through tasks and trading milestones. The balance can also be used for cashback or trading bonus.

    PrimeXBT continues to strengthen its position in multi-asset trading through competitive pricing and professional tools. The VIP Welcome offer reinforces this priority, making market-leading trading conditions accessible to everyone from the very first trade.

    To learn more, users can visit PrimeXBT website.

    About PrimeXBT

    PrimeXBT is a global multi-asset broker and crypto asset service provider trusted by traders in more than 150 countries. The platform bridges traditional and digital markets within one integrated environment, redefining versatility and innovation in online trading. Clients can access Forex, CFDs on indices, commodities, shares, crypto, and Crypto Futures, as well as buy, store and exchange cryptocurrencies. This unified experience extends across both the native PXTrader 2.0 platform and MetaTrader 5, supported by advanced risk-management tools and a wide range of funding options in crypto, fiat and local payment methods. Since 2018, PrimeXBT has focused on empowering traders through broad multi-asset access, fair and transparent conditions, professional-grade technology and dedicated human support. By combining expertise, trust and a client-first approach, PrimeXBT sets a benchmark of excellence in the financial industry and provides traders with the tools they need to trade, grow and succeed with confidence.

    Disclaimer: The content provided here is for informational purposes only and is not intended as personal investment advice and does not constitute a solicitation or invitation to engage in any financial transactions, investments, or related activities. Past performance is not a reliable indicator of future results. The financial products offered by the Company are complex and come with a high risk of losing money rapidly due to leverage. These products may not be suitable for all investors. Before engaging, you should consider whether you understand how these leveraged products work and whether you can afford the high risk of losing your money. The Company does not accept clients from the Restricted Jurisdictions as indicated on its website / T&Cs. Some products and services, including MT5, may not be available in your jurisdiction. The applicable legal entity and its respective products and services depend on the client’s country of residence and the entity with which the client has established a contractual relationship during registration.

    Contact

    PrimeXBT
    pr@primexbt.com